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Abstract
Background: Polyethylene glycol is commonly used to manage constipation and is available with or without
electrolytes. The addition of electrolytes dates back to its initial development as lavage solutions in preparation for
gastrointestinal interventions. The clinical utility of the addition of electrolytes to polyethylene glycol for the management
of constipation is not established.
The objective of this systematic review and network meta-analysis (NMA) was to assess the relative effectiveness
of polyethylene glycol with (PEG + E) or without electrolytes (PEG) in the management of functional constipation
in adults.
Methods: A systematic review was conducted to identify randomised controlled clinical trials that assessed the
use of polyethylene glycol in functional constipation. The primary outcome was the mean number of bowel movements
per week.
Results: Nineteen studies were included in the NMA (PEG N = 9, PEG + E N = 8, PEG versus PEG + E N = 2; involving 2247
patients). PEG and PEG + E are both effective, increasing the number of bowel movements per week by 1.8 (95 %
Crl 1.0, 2.8) and 1.9 (95 % Crl 0.9, 3.0) respectively versus placebo and by 1.8 (95 % Crl 0.0, 3.5) and 1.9 (95 % Crl 0.2, 3.6)
respectively versus lactulose. There was no efficacy difference between PEG + E and PEG (0.1, 95 % Crl −1.1, 1.2) and
there were no differences in safety or tolerability.
Conclusions: Polyethylene glycol with and without electrolytes are effective and safe treatments for constipation in
adults. The addition of electrolytes to polyethylene glycol does not appear to offer any clinical benefits over polyethylene
glycol alone in the management of constipation.
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Background
Constipation is a common gastrointestinal symptom with
a reported mean prevalence of 15 to 17 % amongst the
general population. The prevalence is as high as 81 %
amongst older hospitalised patients and 95 % amongst
patients taking opioid analgesics [1, 2]. Constipation may
adversely impact quality of life and increase the use of
healthcare resources [1]. Together these factors make
constipation an important health issue that needs effective
and safe treatments.
Polyethylene glycol, a minimally absorbed osmotic
laxative, is commonly used to manage constipation in
both adults and children. It is a mixture of different
sized compounds with an approximate mean molecular
weight of either 3350 or 4000 g/mol and is available in
formulations with the addition of electrolytes (PEG + E)
or without electrolytes (PEG). Polyethylene glycol exerts
its laxative action by increasing the water content of
stools due to its ability to interact with water molecules
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[3]. Importantly, its use is not associated with marked
shifts in water from the body, as it essentially only binds
with water that is orally ingested [4]. As it lacks any
electrical charge, it does not influence the movement of
other solutes [3]. Polyethylene glycol is biologically inert
and is not metabolised by colonic bacteria. Therefore, it
is expected to exert its full osmotic effect with fewer side
effects (such as bloating and flatulence) than the non-
absorbable sugar laxatives, as there is no fermentative
production of intestinal gas [4, 5].
Polyethylene glycols were first used in lavage solutions
in preparation for gastrointestinal interventions such as
colonoscopy or bowel surgery [4]. For this indication,
they are given in high doses and are generally adminis-
tered with electrolytes to reduce the risk of large electro-
lyte shifts [4, 6]. Later, lower doses were used for the
management of constipation. More recent formulations
were developed without electrolytes to reduce the
sodium load, improve taste and potentially patient
acceptance and compliance also [3].
The clinical effectiveness of polyethylene glycols in the
management of constipation in adults is well established
and confirmed in a recent meta-analysis by Belsey et al.
[7]. This analysis demonstrated that polyethylene glycol
is more effective than placebo and active comparators
such as lactulose in the treatment of non-organic consti-
pation. In this analysis however, all polyethylene glycol
formulations were treated as the same and it did not
provided any insight regarding the clinical utility of the
addition of electrolytes to polyethylene glycol. In some
countries PEG + E is more widely used than PEG for the
management of constipation [8]. The reasons for this are
multifactorial and include the perception that PEG + E is
a more effective treatment for constipation and safer in
terms of preventing electrolyte imbalance. There how-
ever is a lack of evidence to support or refute these
perceptions.
The objective of this systematic review and network
meta-analysis (NMA) was to assess the relative effective-
ness of polyethylene glycol with or without electrolytes
in the management of functional constipation in adults.
The primary end point was the difference in the mean
number of bowel movements per week. Secondary end-
points relate to the relative safety, tolerability and com-




Text word searches were carried out using MEDLINE,
MEDLINE in Progress, EMBASE, and the Cochrane data-
bases covering inception to April 2015. Search terms were
(constipation) AND (PEG OR polyethylene OR macrogol
OR movicol OR idrolax OR miralax OR transipeg OR
forlax OR colyte OR golytely OR isocolan OR nulytely)
NOT colonoscopy. Studies were included in the final ana-
lysis if they met the following criteria: published rando-
mised controlled trials comparing oral polyethylene glycol
with placebo or a comparator laxative in patients with
constipation. A diagnosis of constipation could be based
on clinical symptoms, a physician’s opinion, or the Rome
I, II or III diagnostic criteria. Bibliographies of all identi-
fied relevant studies and reviews were used to perform a
recursive search. Only studies conducted in adults and
published in English, excluding conference proceedings,
were included in the analysis. Attempts were made to
contact the authors of several studies for additional infor-
mation about their data, with one successful response
received.
Data extraction
Two reviewers were involved in a four-step approach for
data collection. All steps were performed independently.
First, titles and abstracts of the identified citations were
screened to see if they met the study selection criteria.
Full texts of potentially relevant articles were reviewed
to assess if they met the selection criteria. For the stud-
ies that did meet the selection criteria, one reviewer con-
ducted extraction of data using a standardised Excel
spreadsheet. A second reviewer independently confirmed
the accuracy of the extracted data. As the final step, both
reviewers determined if the study was to be included in the
systematic review and network meta-analysis. Disagree-
ments were resolved by consensus involving an additional
two reviewers.
The following study characteristics were extracted:
author; title; journal; publication year; population (adult/
paediatric); study design; patient age; characteristics;
definition of constipation; inclusion/exclusion criteria;
intent to treat population (ITT); per protocol population
for defecation frequency; mean duration of constipation
prior to study intervention; comparability of study
groups; sub-analysis based on age; study duration; study
medications, dose and duration of treatment. To avoid
comparisons of different subjective composite measures
of efficacy, a single objective outcome was selected for the
primary analysis – mean number of bowel movements
per week. Assessment of defaecation frequency was made
after a 2-week treatment period (if available) or at end of
treatment (mean plus standard deviation [SD] or standard
error [SE]). When data was available for both bowel move-
ments and complete spontaneous bowel movements per
week the later data was used in the analysis. Where data
was only available graphically, estimates of the values
were extracted by scaled measurement. Where means
were not available, medians and interquartile ranges
were collected. All data were adjusted to mean number
of bowel movements per week (plus standard deviation)
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to allow meaningful comparison between the studies.
To assess secondary endpoints, data regarding safety,
tolerability, and compliance or willingness to continue
therapy were collected.
All included studies were assessed for the risk of bias
by two reviewers according to recommendations out-
lined in the Cochrane Handbook for Systematic Reviews
of Interventions [9]. Each potential source of bias was
graded as high, low or unclear, relating to whether the
potential for bias was low or high. Studies were consid-
ered as high quality if all of the criteria were graded as
low risk of bias.
Data synthesis (statistical analysis)
Studies included in the analysis were grouped according
to whether the polyethylene glycol investigated included
electrolytes (PEG + E) or not (PEG) and then according
to the comparator (placebo or different active controls).
For all pairings where there was more than one study a
direct estimate of the difference in mean number of bowel
movements per week has been obtained using both a
Bayesian fixed effects and a Bayesian random effects
model (i.e. a standard meta-analysis) using SAS v9.3. In
addition, all the available data have been combined using
a network meta-analysis with a Bayesian random effects
model fitted to assess the relative effectiveness of PEG and
PEG + E [10]. NMA was used as it allows an estimation of
comparative effects to be made between two treatments
that have not been sufficiently investigated by head to
head randomised clinical trials [11]. The percentage of
simulations where active treatment had a mean stool fre-
quency greater than for control was obtained and is re-
ported as a percentage, ‘probability best’. In this analysis, if
the two treatments are equivalent, then the active treat-
ment would be greater than the control 50 % of the time,
and hence the ‘probability best’ equals 50 %. If the active
is better than the control in all simulations the probability
best equals 100 %.
The mean stool frequency was treated as a continuous
outcome and hence a generalized linear model with iden-
tity link and a normal likelihood distribution was fitted
using SAS v9.3 PROC MCMC. Vague (flat) priors were
used for all calculations. A normal distribution (0, 106)
was used for treatment effects and a uniform (0.01, 5) for
inter-study standard deviation. Each analysis was run with
200,000 simulations, 1000 burn-in and thin = 20. The
sensitivity of the results to study quality was explored by




An overview of the study selection process is summarised
in Fig. 1. Literature searches identified 1612 potentially
relevant abstracts that after elimination of duplicates
was reduced to 1484. After review of the abstracts, 36
full-text publications were assessed of which 20 studies
were included in the final systematic review and 19 in
the NMA [12–31].
Study characteristics
Of the 20 qualifying studies; nine studies compared PEG
versus placebo (N = 7), lactulose (N = 1) or serotonin
agonist (N = 1); nine studies compared PEG + E versus
placebo (N = 5), lactulose (N = 1), serotonin agonist (N = 1)
or bulk forming laxative (N = 1), plus one study involved
both an active (lactulose) and placebo control group; and
two studies made direct comparisons between PEG and
PEG+ E. Table 1 summarises the design of each of the in-
dividual studies. One study, Corazziaria 2000 [21] was not
included in the NMA as all patients had responded to
treatment during the run-in phase and had normal bowel
function at the time of randomisation. This study however
was included in the systematic review to evaluate relevant
safety and tolerability data.
Overall, of the 19 studies included in the NMA, 2247
patients had been randomised to either one of the poly-
ethylene glycols, placebo or active control. All studies
had comparable study populations at baseline or used a
crossover design. All studies were randomised clinical
trials and all but 4 studies were blinded. Four of the
studies were assessed as being of low risk of bias based
on the recommendations outlined in the Cochrane
Handbook for Systematic Reviews of Interventions [9].
(Table 2).
In the majority of the studies (N = 11) patients had
chronic constipation, [12, 13, 15, 17, 18, 20, 25, 26, 28–30]
in four studies patients had a history of constipation,
[14, 19, 22, 23] in two studies constipation was second-
ary to medication use [24, 27] and in two studies con-
stipation was related to underlying disease, Parkinson’s
Disease [31] and irritable bowel syndrome [16]. Overall
more female patients (86.7 %) were assessed in these
studies and the average patient age ranged from 30.7 to
86 years.
Network meta-analysis
Figure 2 presents the network diagram based on the 19
studies included in the NMA, showing a total of 26 con-
nections between the comparators. The individual study
results for the mean number of bowel movements per
week from the included trials are presented in Table 2.
Some publications contribute more than one data set
due to multiple comparator groups, e.g. high and low
dose groups, both active and placebo controls, and
multiple studies reported within the one publication.
Table 3 summarises the results for the Bayesian random
effects pairwise meta-analysis for direct evidence. The
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only comparison that was statistically significant was
for PEG versus placebo, with PEG increasing the mean
number of bowel movements per week by 1.8 (95 % Crl
0.2, 3.6). The direct comparison between PEG and PEG
+ E failed to show any significant efficacy difference
(−0.5, 95 % Crl,-4.5, 3.3) (Fig. 3).
Table 3 and Fig. 4 summarise the results of the NMA.
With the inclusion of more data in the NMA, this ana-
lysis suggests that both PEG and PEG + E are more ef-
fective than both placebo and lactulose, increasing the
mean number of bowel movements per week by 1.8
(95 % Crl 1.0, 2.8) and 1.9 (95 % Crl 0.9, 3.0) respect-
ively versus placebo and by 1.8 (95 % Crl 0.0, 3.5) and
1.9 (95 % Crl 0.2, 3.6) respectively versus lactulose.
Comparisons of PEG and PEG + E with bulk forming
laxatives and serotonin (5-HT4) agonists were not sta-
tistically significant. The direct comparison of PEG + E
and PEG suggests that the difference in the mean num-
ber of bowel movements per week is negligible and not
statistically significant (0.1, 95 % Crl −1.1, 1.2). The
relative effectiveness of both PEG and PEG + E versus
placebo was maintained with sensitivity analysis includ-
ing only studies with a low risk of bias.
Safety and tolerability
Twelve studies included in the systematic review provided
data on the safety of polyethylene glycol [13, 17–19, 21–
25, 29–31] and all but one study provided tolerability data
[12–27, 29–31] (Table 4). Overall, there were no clinically
relevant changes in laboratory measures or vital signs,
with the exception of one case of mild hypokalaemia in a
patient taking PEG + E with concurrent diuretic use [13].
Polyethylene glycol with or without electrolytes was well
tolerated with most events being mild to moderate in
severity. The more common adverse events included
abdominal pain, diarrhoea, loose stools, nausea and ab-
dominal distension. In addition, two PEG + E studies
reported issues regarding poor taste as an adverse event,
[12, 31] whilst taste was not reported as an issue with the
use of PEG. Amongst the placebo-controlled studies, three
of the seven PEG [14, 23, 24] and two of the five PEG + E
studies [20, 21] specifically reported no differences in
Fig. 1 Flow chart of study selection
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Table 1 Summary of the included studies



























Chronic 87.5 % ≤ 2
stools/week
Continued use of fibre
and bulk-forming
agents. Laxatives
or enemas for treatment
failure: P = 12.5 %,
C = 18.8 %
P1: 62 P1: 25 % PEG3350 + E High dose 16 Placebo 16
P2: 58 P2: 19 % High dose 16 oz Low dose 16
Low dose 8 oz
Attar A
1999 [13]
115 4 weeks Chronic Not specified Suppositories,
micro-enemas
allowed. Any use:
P = 16 %, C = 34 %
P: 55 (24) P: 15 % PEG3350 + E 60 Lactulose 55
C: 55 (22) C: 22 % 13–39 g 10–30 g
Awad RA
2010 [14]
47 30 days Irritable bowel
syndrome (IBS-C)
P: 1.3 (0.6) Not allowed. P: 1 use of
glycerine suppository
P: 30.7 (8) 12 % PEG3350 23 Placebo 24
C: 1.5 (0.7) C: 1 use of enema C: 36.5 (10) 10.35 g
Bouhnik Y
2004 [15]
65 28 days Chronic,
idiopathic




stopped 48 hours before
baseline. 9 % of patients
took concomitant treatment
at study entry and all
were stopped










if no bowel movement for 3
consecutive days. Mean No.
weekly rescue doses: P = 0.30,
C = 0.44






266 2 weeks Chronic,
idiopathic
P(H): 2.0 (0.9) Rescue medication
suppository if no bowel
movement for 3 consecutive
days. Stools post-suppository
use were not included in
study results
52.2 (18.5) 15 % PEG3350 + E High dose 69 PEG4000
High dose 20 g
High dose
67
P(L): 2.2 (1.3) High dose 11.8 g Low dose 69 Low dose 10 g Low dose
65




240 2 weeks Chronic P: 0.7 (0.8) Rescue medication ducosate
micro-enema if no bowel
movement for 3 consecutive
days. Use of micro-enema:
P = 0.8 %, C = 3.4 %












2.6 (1.75) Not allowed 47.7 4 % PEG3350 10.35 g 23 Placebo 23
Corazziari E
1996 [20]
55 4 weeks Chronic P: 2.2 (0.5) Rescue medication, laxatives
if no bowel movement for
5 consecutive days.
Use of laxatives:
P = 16 %, C = 48 %
41.8 (14.8) P: 32 % PEG4000 + E 17.5 g 25 Placebo 23












Table 1 Summary of the included studies (Continued)
Corazziari E
2000 [21]
70 20 weeks Chronic P: 1.53 (1.35) Rescue medication,
laxatives if no bowel
movement for 5
consecutive days.
Use of laxatives was
less frequent in
PEG + E than placebo
(P < 0.001)








Not specified Not allowed AM: 36.2 AM: 6 % PEG3350 AM high
dose: 50
Placebo AM: 50
LT: 75.7 LT: 46 % AM high dose: 34 g AM low
dose: 50
LT: 17
AM low dose: 17 g LT high
dose: 17
LT high dose: 12 g LT low dose:
17
LT low dose: 6 g
Di Palma JA
2000 [23]
151 14 days History of
constipation
Not specified Not allowed 45.2 13 % PEG3350 17 g 80 Placebo 71
Di Palma JA
2007A [24]
100 4 Weeks Secondary to
medications
Not specified Fibre or other laxatives
not allowed
58 26 % PEG3350 17 g 46 Placebo 46
Di Palma JA
2007B [25]




bisacodyl if no bowel
movement for 4
consecutive days.
Mean use of bisacodyl
5 mg: P = 2.8, C = 3.9
tablets/week
53 15 % PEG3350 17 g 202 Placebo 100








bisacodyl if no bowel
movement for 4
consecutive days.
Mean use of bisacodyl
5 mg: P = 1.4, C =
1.0 tablets/week








Opioid-induced Not specified Additional milk of
magnesia or bisacodyl
allowed. No difference
























Chronic Median 3 Sodium picosulfate was
allowed except for the
last week of each study
period. Median drops
per day: P = 0, C = 4
46 (4) 0 % PEG4000 60 g 8 Placebo 8
Seinela L
2009 [29]
65 4 weeks Chronic
functional







for 3 consecutive days.
Use of suppositories:
PEG + E = 12.5 %
86 34 % PEG4000 + E 6–24 g 32 PEG4000 6–24 g 30
C: 8.4
PEG = 3.3 %
Wang H 2005
[30]
126 2 weeks Chronic
functional
P: 1.18 (0.77) Not allowed P: 51. 2 (14.8) 40 % PEG3350 + E 27.6 g 63 Isphagula husk 7 g
(bulk forming)
63
C: 1.33 (0.68) C: 50.0 (17.1)
Zangaglia R
2007 [31]





P: 1.9 (0.56) Rescue medication,
rectal laxatives. Use
of rectal laxatives:
P = 4.3 % week 4 &
0 % week 8
71.0 (6.5) 60 % PEG4000 + E 7.3–21.9 g 29 Placebo 28
C: 2.0 (0.6) C = 9.5 % week 4 &
12.5 % week 8












tolerability versus placebo, whilst 1 study for PEG [25]
and two studies for PEG + E [16, 31] reported a higher
incidence of side effects versus placebo. Studies that
directly compared PEG with PEG + E demonstrated no
differences in tolerability, [17, 29] with the exception that
in one study there were four serious events leading to
discontinuation with PEG + E, but no cases with PEG
[29]. Eleven patients (1.8 %) discontinued therapy due
to adverse events with PEG + E compared to three
patients (0.4 %) with PEG. Reasons for discontinuation
with PEG + E included abdominal pain, abdominal rigid-
ity, abdominal bloating, nausea, diarrhoea, anal fissure and
poor taste. Reasons for discontinuation with PEG were
abdominal pain and distention.
Compliance, willingness to continue therapy
Only two studies provided data on patient compliance
or willingness to continue polyethylene glycol therapy.
In a placebo-controlled study, compliance was lower
with PEG + E as assessed by the mean number of sachets
used per week [16]. In a direct comparison of PEG and
PEG + E, more patients were willing to continue with
PEG therapy (85 % vs 63 %), but this difference was not
statistically significance (p = 0.07) [29].
Table 2 Individual study results included in the network meta-analysis
Study Assessment
timea
Stools per week (number of patients) Low risk




Awad RA 2010 [14] 30 days 4.1 (N = 23) 4.0 (N = 24) Yes
Cleveland MV 2001 [19] 14 days 7.0 (N = 23) 3.6 (N = 23) No
Di Palma JA 1999 [22] (AM high dose) 10 days 5.6 (N = 50) 3.2 (N = 50) No
Di Palma JA 1999 [22] (AM low dose) 10 days 3.8 (N = 50) 3.2 (N = 50) No
Di Palma JA 1999 [22] (LT high dose) 10 days 4.9 (N = 17) 4.1 (N = 17) No
Di Palma JA 1999 [22] (LT low dose) 10 days 3.2 (N = 17) 4.1 (N = 17) No
Di Palma JA 2000 [23] 14 days 4.5 (N = 80) 2.7 (N = 71) No
Di Palma JA 2007A [24] 14 days 8.9 (N = 46) 5.6 (N = 46) Yes
Di Palma JA 2007B [25] 14 days 7.9 (N = 202) 5.6 (N = 100) No
Klauser AG 1995 [28] 6 weeks 11.0 (N = 8) 3.0 (N = 8) No
Andorsky RI 1990 [12] (High dose) 14 days 13.4 (N = 16) 7.5 (N = 16) No
Andorsky RI 1990 [12] (Low dose) 14 days 8.1 (N = 16) 6.1 (N = 16) No
Chapman RW 2013 [16] 4 weeks 4.4 (N = 68) 3.1 (N = 71) Yes
Corazziari E 1996 [20] 4 weeks 4.8 (N = 25) 2.8 (N = 23) No
Freedman MD 1997 [27] 14 days 6.9 (N = 57) 6.5 (N = 57) 5.8 (N = 57) No
Zangaglia R 2007 [31] 8 weeks 6.6 (N = 29) 3.7 (N = 28) No
Chaussade S 2003 [17] (High dose) 2 weeks 6.6 (N = 69) 8.2 (N = 67) No
Chaussade S 2003 [17] (Low dose) 2 weeks 6.9 (N = 65) 6.0 (N = 65) No
Seinela L 2009 [29] 2 weeks 8.7 (N = 32) 9.5 (N = 30) No
Bouhnik Y 2004 [15] 28 days 8.8 (N = 32) 7.8 (N = 33) No
Di Palma JA 2007C [26] 28 days 10.4 (N = 118) 8.5 (N = 116) No
Attar A 1999 [13] 4 weeks 9.1 (N = 60) 6.3 (N = 55) No
Cinca R 2013 [18] 2 weeks 3.2 (N = 120) 2.2 (N = 116) Yes
Wang H 2005 [30] 2 weeks 8.5 (N = 63) 5.7 (N = 63) No
aAssessment time was 14 days after treatment initiated (if available) or at end of treatment
AM Ambulatory healthy outpatients, LT Long term
Fig. 2 Network formed by interventions and their direct comparisons
included in the analyses
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Discussion
The aim of this network meta-analysis was to assess
the relative effectiveness of polyethylene glycol with
and without electrolytes in the management of func-
tional constipation. The addition of electrolytes to
polyethylene glycol did not enhance clinical effective-
ness compared to polyethylene glycol alone.
This NMA and the direct head-to-head random
effects meta-analysis are consistent and confirmed that
both PEG and PEG + E are effective treatments for
constipation. Comparisons with placebo were highly
significant, with PEG and PEG + E increasing the
number of bowel movements per week by 1.8 and
1.9 respectively. These results are consistent with
previously published meta-analysis where polyethylene
glycol (PEG and PEG + E grouped together) was
found to increase the mean number of bowel move-
ments per week by 1.98 versus placebo [7]. Our
results also suggest that both PEG and PEG + E are
more effective than lactulose a result that is also
consistent with other meta-analyses [7, 32, 33]. The
extent of improvement was again similar for both
forms of polyethylene glycol.
No safety signals emerged that would suggest that
the addition of electrolytes provided any safety bene-
fits to the use of polyethylene glycol in the manage-
ment of constipation. Although most of the studies in
this systematic review were of short duration, this






































PEG vs Placebo 1.8 0.2 3.6 2.17 10 1.8 1.0 2.8 100.0 %
PEG + E vs Placebo 2.1 −0.1 4.1 2.09 6 1.9 0.9 3.0 100.0 %
PEG + E vs PEG −0.5 −4.5 3.3 2.81 3 0.1 −1.1 1.2 58.5 %
PEG vs Lactulose 1.8 0.0 3.5 97.6 %
PEG + E vs Lactulose 1.7 −4.2 4.9 3.45 2 1.9 0.2 3.6 98.6 %
PEG vs Serotonin agonist 1.3 −1.0 3.5 87.7 %
PEG + E vs Serotonin agonist 1.4 −0.9 3.7 89.2 %
PEG vs Bulk forming 2.6 −0.8 5.8 93.6 %
PEG + E vs Bulk forming 2.6 −0.5 5.8 95.1 %
NMA network meta-analysis, MA meta-analysis aNote a probability of 50 % equates to no difference between the two therapies
Direct head-to-head random effects meta-analysis was performed when there was two or more published studies
Fig. 3 Mean difference in weekly bowel movements PEG + E vs PEG (head-to-head studies)
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finding is consistent with a long-term open label
study of PEG. Over the 12 month study period no
clinically significant changes in haematology or blood
chemistry, particularly electrolytes, were observed
amongst the whole study population or in older par-
ticipants [34].
Overall the tolerability of PEG and PEG + E was
found to be good and often comparable to placebo.
The majority of adverse events were gastrointestinal
and were rated as mild to moderate in severity.
Withdrawals due to adverse events were uncommon
with both PEG + E and PEG. From a safety and tol-
erability perspective the addition of electrolytes to
polyethylene glycol does not appear to provide any
additional clinical benefits in the management of
constipation.
PEG is a tasteless and odourless and can be mixed
with the beverage of the patient’s choice [3]. Although
the data identified in this systematic review is limited,
one double-blind study in 100 adults reported that
PEG was rated as significantly better tasting the PEG
+ E (p < 0.0001) with 84 subjects preferring the taste
of PEG whilst only seven subjects preferred PEG + E
[35]. Palatability may affect willingness to adhere to
therapy [33, 35]. In addition, there is some evidence
of the absorption of electrolytes from low doses of
PEG + E [23] which may need to be considered in
patients with restricted sodium diets.
Limitations
As with any systematic review, the quality of the
studies and the heterogeneity of the study populations
included in the analysis present a limitation of this
study. There were only four studies considered to
have a low risk of bias. Five studies were crossover
studies, only two which had washout periods, [11, 27]
hence there is a risk of a carry-over effect. In one
study the median number of bowel movements per
week were reported rather than the mean. Attempts
to contact the authors for mean data were unsuccess-
ful and the median has been used as the mean since
in a normal distribution these two values would be
equal. Another potential limitation is that constipa-
tion is a subjective complaint and we have used only
one objective measure, the difference in mean num-
ber of bowel movement per week, to assess the rela-
tive efficacy of the different treatments. It was not
possible to conduct a network meta-analysis on the
secondary end point of compliance due to the limited
data and due to differences in the way this was mea-
sured where available. The planned age-related suba-
nalysis was not performed due to the lack of data
specifically reported amongst elderly patients.
Implications for future research
Despite the high prevalence of constipation in the
elderly and the frequent use of laxatives in this pa-
tient population, there is a paucity of clinical trials
evaluating the safety and efficacy of polyethylene
glycol in the elderly. This represents an important
evidence gap.
Conclusions
This network meta-analysis has confirmed that poly-
ethylene glycol with and without electrolytes are ef-
fective and safe treatments for constipation in adults.
Fig. 4 Pairwise comparisons for PEG and PEG + E from the network meta-analysis
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Table 4 Safety and tolerability of polyethylene glycols from the individual studies
Study Type of polyethylene
glycol
Comparator Safety signals (Laboratory data, vital signs) Tolerability (Adverse events)
Andorsky RI
1990 [12]
PEG3350 + E Placebo NA Adverse events with PEG + E were
infrequent and generally tolerable
and included; cramping, gas, nausea,
loose stools, and unpleasant taste.
Attar A
1999 [13]
PEG3350 + E Lactulose No significant changes in laboratory
measurements; except for 1 case of
mild hypokalaemia with concurrent
diuretics. In the 2 month open label
extension study, lower mean serum
folate levels, but all values were
within the normal range.
No differences in tolerability between
the two groups, but flatus was less
frequently reported with PEG + E. 2
adverse events leading to PEG + E
withdrawal; acute diarrhoea with
vomiting and fever; and abdominal
pain. Additional 4 adverse events
leading to drug withdrawal in the
extension study; acute diarrhoea




PEG3350 Placebo NA No difference in tolerability of PEG




PEG4000 Lactulose NA No serious adverse events were
reported. 3 PEG patients
discontinued therapy due to




PEG3350 + E Placebo NA More patients taking PEG 3350 +
E experienced adverse events
compared to placebo (38.8 % vs
32.9 %). No serious adverse
events. The most common
drug-related adverse events
(>3 %); abdominal pain (4.5 %),
diarrhoea (4.5 %). 2 patients
discontinued PEG + E due to
adverse events; abdominal






PEG4000 No clinical issues reported. No differences in tolerability.










68.3 % of patients taking PEG + E
experienced a treatment-emergent
adverse event, mostly mild-moderate
intensity. 5.3 % of the events were
possibly or probably related to PEG +
E. Events included; headache (36.7 %),
nausea (5.8 %), vomiting (2.5 %) and
abdominal pain (2.5 %), UTI (3.3 %).




PEG3350 Placebo No clinically significant
differences in blood
chemistry, CBC, or urinalysis.
No serious adverse events.
Three cases of loose stools
or mild diarrhoea with PEG.
Corazziari E
1996 [20]
PEG4000 + E Placebo NA No difference in tolerability of
PEG + E vs placebo.
Corazziari E
2000 [21]
PEG4000 + E Placebo No significant changes in heart
frequency, blood pressure, blood
count or laboratory measurements.
No difference in tolerability of PEG + E
vs placebo. 2 discontinuations due to
adverse events; abdominal bloating
and fissura in the anus.
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There was no difference in the number of bowel
movements per week and there appears to be no dif-
ferences with respect to safety or tolerability between
the two preparations. The addition of electrolytes in
this clinical setting does not appear to offer any clin-
ical benefits over polyethylene glycol alone.
Table 4 Safety and tolerability of polyethylene glycols from the individual studies (Continued)
Most common adverse events were
nausea and epigastric pain/discomfort.
Di Palma JA
1999 [22]
PEG3350 Placebo No clinically significant
changes in laboratory
measurements.
Ambulatory care patients: dose-related
diarrhoea or loose stools. Long-term
care patients: 5 serious adverse events,
but all were due to pre-existing
conditions and not PEG use.
Di Palma JA
2000 [23]
PEG3350 Placebo No statistically or clinically
significant differences in
laboratory measurements.




PEG3350 Placebo No clinically significant




No statistical difference in tolerability
of PEG vs placebo.
Di Palma JA
2007B [25]
PEG3350 Placebo No clinically significant
changes in laboratory
measurements.
No differences in adverse events
between PEG and placebo except
for gastrointestinal complaints
(PEG 39.7 %, placebo 25 %, P = 0.015).
GI events included abdominal
distension, diarrhoea, loose stools,
flatulence, and nausea. Most events
were mild or moderate. No difference
in tolerability of PEG + E vs placebo
amongst elderly patients.
Di Palma JA 2007C
[26]
PEG3350 Tegaserod NA No serious adverse events. Adverse
events (>3 %) with PEG were;




PEG3350 + E Placebo
Lactulose
NA No difference in frequency of gas
or severe cramping with PEG +
E vs control.
Klauser AG 1995 [28] PEG4000 Placebo NA NA
Seinela L 2009 [29] PEG4000 + E and
PEG4000
PEG4000 Small, but not clinically
relevant changes in
plasma sodium level;
PEG mean decrease from
138.8 to 137.7 mmol/L;
PEG + E mean increase
from 138.6 to 138.9 mmol/L
(P = 0.012). No other significant
differences between the groups
in any of the other electrolyte
or laboratory safety variables,
or in heart rate, blood pressure
or weight.
Low incidence of mild to moderate
adverse events in both groups. Four
serious adverse events with PEG + E;
1 leading to discontinuation of
PEG + E, but none with PEG.
Wang H 2005 [30] PEG3350 + E Isphagula husk No change in mean sodium,
potassium or chloride ion
levels.
No differences in adverse events
between PEG + E and isphagula
husk. No serious events. Most
common adverse event for
PEG + E was dizziness (5 %).




A higher rate of withdrawals
with PEG + E vs placebo
(31 % vs. 18 %). 4 drug-related
discontinuations were due to
nausea, diarrhoea, poor
treatment compliance due to
the taste or volume of preparation.
NA No applicable data reported, AM Ambulatory healthy outpatients, LT Long term
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